You may have recently heard about the multimillion-dollar donation that Bill Gates and Leonard Lauder made to support research into biomarkers for early detection of Alzheimer’s disease and related dementias.
The Diagnostics Accelerator initiative is part of the Alzheimer’s Drug Discovery Foundation’s (ADDF) effort to speed diagnosis and develop drugs that can prevent, treat, and cure the disease. Lauder was an ADDF co-founder. Continue reading
In my most recent post, I recapped what Georgetown University’s Sabrina Corlette, who is also a former Senate health policy aide, told us on an AHCJ webcast about association health plans. This post looks at the second part of the webinar, about short term limited duration plans. Both are options expanded by the Trump administration that may undermine the ACA markets. You can see her slides and listen to the webcast here.
It is worth nothing that health insurance remains very expensive for people who are trying to buy coverage on the individual market who do not quality for income-related subsidies in the ACA exchanges. Continue reading
A mainstay of health reporting is covering outbreaks of foodborne illness, whether it’s salmonella in peanut butter (and its criminal consequences) or listeria in cantaloupes or ice cream. While the Centers for Disease Control and Prevention maintains a robust site documenting food-borne illness outbreaks, by the time the CDC cites a case on its website, the outbreak often already been in the news since potential outbreaks are first investigated by local and state health departments.
How do these smaller agencies decide how and when to publicize details about a suspected or confirmed outbreak? Continue reading
With thousands of medical studies published every day, it’s impossible to cover even 1 percent of them. When you can only choose a tiny fraction of studies to cover — particularly if you freelance or your editor gives you some autonomy and flexibility in this area — how do you decide whether or not to cover a study?
Reasons can vary: Some people focus on the better known “more prestigious” journals, although that approach has its drawbacks. Continue reading
A recent editorial in the Journal of the American Medical Association explored the responsibility that journals have to public health in reporting on the association – or lack thereof – between adverse events and different drugs, devices or vaccines.
Reporting on these kinds of studies is a mainstay for most regular health beat reporters: Every week a new study says that this drug may increase the risk of that condition, or that this device is no longer thought to increase the risk of some other condition.
While the editorial points out the journal’s responsibility in publishing these studies, so that doctors can discuss risks of treatment possibilities with their patients, what is a journalist’s responsibility on reporting these findings? And how do journalists avoid fatigue – and help their readers avoid fatigue – with findings that regularly contradict each other (eggs and heart disease, anyone?) or that have been reported dozens of times already but never go away (e.g., vaccines not causing autism)? Continue reading
In June 2009, Atul Gawande wrote an influential New Yorker article, about the community of McAllen, Texas, which has some of the highest per-capita Medicare costs in the nation. At the time, “The Cost Conundrum” had a significant impact on the national debate over the legislation that would become the Affordable Care Act – not so much on the health insurance coverage aspects but about wasteful spending and flawed incentives built into our payment system.
McAllen was awash in waste, fraud and abuse, with millions spent on care of little to no value to the patient. The spending could not be blamed on socio-economic factors because nearby El Paso was a very similar community, but with half the per capita Medicare costs, and same or better outcomes. Gawande wrote this about McAllen: Continue reading